home > news > detailed info

Abrasion-Resistant and Award-Winning: TEVA Relies on Schreiner MediPharm for Novel Adrenaline Injector Label

Schreiner MediPharm

Patients suffering from life-threatening allergies always carry a life-saving companion with them: an adrenaline autoinjector in order to immediately inject themselves in the event of an anaphylactic shock and to thus counter an allergic reaction. For the emergency drug epinephrine from TEVA, Schreiner MediPharm developed an Autoinjector-Label with special protection against abrasion. Thus, the vital user and product information remains perfectly legible over an extended period of time. The label won an award in the 2019 TLMI Competition.

Epinephrine is a prescription drug for the treatment of life-threatening allergic emergencies. TEVA, a worldwide leader in generic drugs and specialty medicines, offers the adrenaline in single-dose, prefilled disposable autoinjectors. The label developed by Schreiner MediPharm for this injector is provided with abrasion- and scratch-resistant reverse printing. As a result, it is particularly resistant against chemical and mechanical impacts it is exposed to while the autoinjector is being carried in a purse or backpack, for instance. Due to its special material construction and design that is precisely adapted to the sophisticated shape of the autoinjector, the marking label securely adheres to the device. Thus, the vital information about the product and its use is reliably legible and readily available at all times. An additional cover protecting the label against abrasion or separation is not necessary, which reduces waste and the environmental footprint. For product and patient safety, the label features a perforation that clearly and irreversibly indicates any first opening of the cap and thus any potential tampering attempt.

The TEVA Autoinjector-Label won recognition in the yearly North American Tag and Label Manufacturers Institute (TLMI) Competition that awarded Schreiner MediPharm’s product development with second place in the “Multi-Process” category in 2019.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at

For additional information, contact:
Schreiner MediPharm, a business unit of
Schreiner Group GmbH & Co. KG
Bruckmannring 22
85764 Oberschleissheim Germany
Phone +49 89 31584-5400
Fax +49 89 31584-5422
phone +49 89 31584-5400
email Bruckmannring 22, 85764 Oberschleissheim, Germany
Print this page
Send to a friend
News and Press Releases

Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the Phase III POLO trial, which were published in The New England Journal of Medicine.
More info >>

White Papers

Preparation of Pharmaceutical Samples for Metals Analysis


There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement